Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Hey Blur,

No guarantees on anything, as usual. I agree with the sentiment that an accretive cash deal, even one that's relatively modest, will help to prop us into a "fairer" market cap, which, judging by NTGN's recent performance, should be at the very least $200 million.

Considering the market is valuing the whole of ADXS's tech at approximately $0, I think we're in a time of irrational share price depression, one that we could very well come out of at any time, for any reason (or no reason).

Delisting is a potential concern, but I don't think it will happen. At worst, a reverse split would be implemented. The company doesn't die in that case, but current shareholders will be upset.

Re: dilution, I would treat it as a foregone conclusion at this point. Hopefully they'll be able to raise funds on better terms, though.

Re: trading in the $8 range, be careful what you wish for. A 10:1 R/S would get you there today.

Overall, there is a lot of uncertainty, and quite a lot of investors do not want to touch ADXS as a result. This builds on the risk proposition, but there are still quite a few catalysts generally around the corner that could turn the entire situation on its head. That's part of the reason I remain invested here.